<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
		<meta http-equiv="Content-Style-Type" content="text/css" />
		<meta name="generator" content="MediaWiki 1.15alpha" />
		<meta name="keywords" content="Ibogaine,TiHKAL,18-methoxycoronaridine,2,Alpha-DMT,2,N,N-TMT,2-Me-DET,2006,4,5-MDO-DMT,4,5-MDO-DiPT,4-HO-DBT,4-HO-DET" />
		<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Ibogaine&amp;action=edit" />
		<link rel="edit" title="Edit this page" href="/w/index.php?title=Ibogaine&amp;action=edit" />
		<link rel="apple-touch-icon" href="http://en.wikipedia.org/apple-touch-icon.png" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
		<link rel="copyright" href="http://www.gnu.org/copyleft/fdl.html" />
		<link rel="alternate" type="application/rss+xml" title="Wikipedia RSS Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=rss" />
		<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
		<title>Ibogaine - Wikipedia, the free encyclopedia</title>
		<link rel="stylesheet" href="/skins-1.5/common/shared.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/common/commonPrint.css?207xx" type="text/css" media="print" />
		<link rel="stylesheet" href="/skins-1.5/monobook/main.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/chick/main.css?207xx" type="text/css" media="handheld" />
		<!--[if lt IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE50Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE55Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 6]><link rel="stylesheet" href="/skins-1.5/monobook/IE60Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 7]><link rel="stylesheet" href="/skins-1.5/monobook/IE70Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Common.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Print.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="print" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Handheld.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="handheld" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Monobook.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=-&amp;action=raw&amp;maxage=2678400&amp;gen=css" type="text/css" />
		<!--[if lt IE 7]><script type="text/javascript" src="/skins-1.5/common/IEFixes.js?207xx"></script>
		<meta http-equiv="imagetoolbar" content="no" /><![endif]-->

		<script type= "text/javascript">/*<![CDATA[*/
		var skin = "monobook";
		var stylepath = "/skins-1.5";
		var wgArticlePath = "/wiki/$1";
		var wgScriptPath = "/w";
		var wgScript = "/w/index.php";
		var wgVariantArticlePath = false;
		var wgActionPaths = {};
		var wgServer = "http://en.wikipedia.org";
		var wgCanonicalNamespace = "";
		var wgCanonicalSpecialPageName = false;
		var wgNamespaceNumber = 0;
		var wgPageName = "Ibogaine";
		var wgTitle = "Ibogaine";
		var wgAction = "view";
		var wgArticleId = "2104803";
		var wgIsArticle = true;
		var wgUserName = null;
		var wgUserGroups = null;
		var wgUserLanguage = "en";
		var wgContentLanguage = "en";
		var wgBreakFrames = false;
		var wgCurRevisionId = 281154218;
		var wgVersion = "1.15alpha";
		var wgEnableAPI = true;
		var wgEnableWriteAPI = true;
		var wgSeparatorTransformTable = ["", ""];
		var wgDigitTransformTable = ["", ""];
		var wgMWSuggestTemplate = "http://en.wikipedia.org/w/api.php?action=opensearch\x26search={searchTerms}\x26namespace={namespaces}\x26suggest";
		var wgDBname = "enwiki";
		var wgSearchNamespaces = [0];
		var wgMWSuggestMessages = ["with suggestions", "no suggestions"];
		var wgRestrictionEdit = [];
		var wgRestrictionMove = [];
		/*]]>*/</script>

		<script type="text/javascript" src="/skins-1.5/common/wikibits.js?207xx"><!-- wikibits js --></script>
		<!-- Head Scripts -->
		<script type="text/javascript" src="/skins-1.5/common/ajax.js?207xx"></script>
		<script type="text/javascript" src="/skins-1.5/common/mwsuggest.js?207xx"></script>
<script type="text/javascript">/*<![CDATA[*/
var wgNotice='';var wgNoticeLocal='';
/*]]>*/</script>		<script type="text/javascript" src="http://upload.wikimedia.org/centralnotice/wikipedia/en/centralnotice.js?207xx"></script>
		<script type="text/javascript" src="/w/index.php?title=-&amp;action=raw&amp;gen=js&amp;useskin=monobook"><!-- site js --></script>
	</head>
<body class="mediawiki ltr ns-0 ns-subject page-Ibogaine skin-monobook">
	<div id="globalWrapper">
		<div id="column-content">
	<div id="content">
		<a name="top" id="top"></a>
		<div id="siteNotice"><script type='text/javascript'>if (wgNotice != '') document.writeln(wgNotice);</script></div>		<h1 id="firstHeading" class="firstHeading">Ibogaine</h1>
		<div id="bodyContent">
			<h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
			<div id="contentSub"></div>
									<div id="jump-to-nav">Jump to: <a href="#column-one">navigation</a>, <a href="#searchInput">search</a></div>			<!-- start content -->
			<table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="/wiki/File:Ibogaine.svg" class="image" title="Ibogaine.svg"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/c/cf/Ibogaine.svg/180px-Ibogaine.svg.png" width="180" height="86" border="0" /></a></td>
</tr>
<tr>
<td align="center" colspan="2"><a href="/wiki/File:Ibogaine-3d-sticks.png" class="image" title="Ibogaine-3d-sticks.png"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/5/52/Ibogaine-3d-sticks.png/180px-Ibogaine-3d-sticks.png" width="180" height="93" border="0" /></a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Ibogaine</div>
</td>
</tr>
<tr>
<td align="center" colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="/wiki/International_Union_of_Pure_and_Applied_Chemistry_nomenclature" title="International Union of Pure and Applied Chemistry nomenclature" class="mw-redirect">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">12-Methoxyibogamine</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="/wiki/CAS_registry_number" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=83-74-9&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=83-74-9&amp;rn=1" rel="nofollow">83-74-9</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/PubChem" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=363272" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=363272" rel="nofollow">363272</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.chemspider.com/Chemical-Structure.170667" class="external text" title="http://www.chemspider.com/Chemical-Structure.170667" rel="nofollow">170667</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="/wiki/Carbon" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>20</sub><a href="/wiki/Hydrogen" title="Hydrogen"><span style="color: rgb(77,77,77); font-weight: bold;">H</span></a><sub>26</sub><a href="/wiki/Nitrogen" title="Nitrogen"><span style="color: rgb(0,0,128); font-weight: bold;">N</span></a><sub>2</sub><a href="/wiki/Oxygen" title="Oxygen"><span style="color: rgb(116,35,35); font-weight: bold;">O</span></a><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Molecular_mass" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">310.433 g/mol</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Simplified_molecular_input_line_entry_specification" title="Simplified molecular input line entry specification">SMILES</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.emolecules.com/cgi-bin/search?t=ex&amp;q=CCC1CC2CC3C1N%28C2%29CCC4%3DC3NC5%3DC4C%3DC%28C%3DC5%29OC" class="external text" title="http://www.emolecules.com/cgi-bin/search?t=ex&amp;q=CCC1CC2CC3C1N%28C2%29CCC4%3DC3NC5%3DC4C%3DC%28C%3DC5%29OC" rel="nofollow">eMolecules</a></span> &amp; <span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/search/?smarts=CCC1CC2CC3C1N%28C2%29CCC4%3DC3NC5%3DC4C%3DC%28C%3DC5%29OC" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/search/?smarts=CCC1CC2CC3C1N%28C2%29CCC4%3DC3NC5%3DC4C%3DC%28C%3DC5%29OC" rel="nofollow">PubChem</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Physical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Melting_point" title="Melting point">Melt. point</a></td>
<td bgcolor="#EEEEEE">152–153&#160;°C (306–307&#160;°F)</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Bioavailability" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Drug_metabolism" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Biological_half-life" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">2 hours</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Excretion" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>?</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE">
<p><a href="/wiki/Controlled_Substances_Act#Schedule_I_drugs" title="Controlled Substances Act">Schedule I</a><small>(<a href="/wiki/United_States" title="United States">US</a>)</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE">oral</td>
</tr>
</table>
<div class="floatright"><a href="/wiki/File:Ibogaine.jpg" class="image" title="Ibogaine"><img alt="Ibogaine" src="http://upload.wikimedia.org/wikipedia/commons/thumb/2/28/Ibogaine.jpg/150px-Ibogaine.jpg" width="150" height="135" border="0" /></a></div>
<p><b>Ibogaine</b> is a naturally occurring <a href="/wiki/Psychoactive_drug" title="Psychoactive drug">psychoactive</a> compound found in a number of plants, principally in a member of the <a href="/wiki/Apocynaceae" title="Apocynaceae">dogbane family</a> known as iboga (<i><a href="/wiki/Tabernanthe_iboga" title="Tabernanthe iboga">Tabernanthe iboga</a></i>). Ibogaine-containing preparations are used in medicinal and ritual purposes within <a href="/wiki/Africa" title="Africa">African</a> spiritual traditions of the <a href="/wiki/Bwiti" title="Bwiti">Bwiti</a>, who claim to have learned it from the <a href="/wiki/Pygmy" title="Pygmy" class="mw-redirect">Pygmy</a>. In recent times, it has been identified as having <a href="/wiki/Anti-addictive" title="Anti-addictive" class="mw-redirect">anti-addictive</a> properties. Ibogaine is an <a href="/wiki/Indole" title="Indole">indole</a> <a href="/wiki/Alkaloid" title="Alkaloid">alkaloid</a> that is obtained either by extraction from the iboga plant or by semi-synthesis from the precursor compound <a href="/wiki/Voacangine" title="Voacangine">voacangine</a>, another plant alkaloid. A full organic synthesis of ibogaine has been achieved but is too expensive and challenging to produce any commercially significant yield.</p>
<p>In the early 1960s, ibogaine was accidentally discovered to cause sudden and complete interruption of <a href="/wiki/Heroin" title="Heroin">heroin</a> addiction without withdrawal in a matter of hours. Since that time, it has been the subject of scientific investigation into its abilities to interrupt addictions to heroin, <a href="/wiki/Alcohol" title="Alcohol">alcohol</a>, and <a href="/wiki/Cocaine" title="Cocaine">cocaine</a>. Anecdotal reports also suggest that ibogaine may have potential to drive introspection that helps elucidate the psychological issues and behavior patterns that drive addictions or other problems. However, ibogaine therapy for drug addiction is the subject of some controversy. Due to its <a href="/wiki/Hallucinogenic" title="Hallucinogenic" class="mw-redirect">hallucinogenic</a> properties, it has been placed in the strictest drug prohibition schedules in the United States and a handful of other countries. Canada and Mexico both allow ibogaine treatment clinics to operate and openly contribute to further understanding of the addictive process.</p>
<p>While ibogaine's <a href="/wiki/Prohibition_(drugs)" title="Prohibition (drugs)">prohibition</a> has slowed scientific research into its anti-addictive properties, the use of ibogaine for drug treatment has grown in the form of a large worldwide medical <a href="/wiki/Subculture" title="Subculture">subculture</a>.<sup id="cite_ref-0" class="reference"><a href="#cite_note-0" title=""><span>[</span>1<span>]</span></a></sup> Ibogaine is now used by treatment clinics in 12 countries on six continents to treat addictions to heroin, alcohol, powder cocaine, crack cocaine, and <a href="/wiki/Methamphetamine" title="Methamphetamine">methamphetamine</a>, as well as to facilitate <a href="/wiki/Transpersonal_psychology" title="Transpersonal psychology">psychological introspection</a> and spiritual exploration.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Psychoactive_effects"><span class="tocnumber">1</span> <span class="toctext">Psychoactive effects</span></a></li>
<li class="toclevel-1"><a href="#Side_effects_and_safety"><span class="tocnumber">2</span> <span class="toctext">Side effects and safety</span></a></li>
<li class="toclevel-1"><a href="#Therapeutic_uses"><span class="tocnumber">3</span> <span class="toctext">Therapeutic uses</span></a>
<ul>
<li class="toclevel-2"><a href="#Treatment_for_opiate_addiction"><span class="tocnumber">3.1</span> <span class="toctext">Treatment for opiate addiction</span></a></li>
<li class="toclevel-2"><a href="#Chronic_pain_management"><span class="tocnumber">3.2</span> <span class="toctext">Chronic pain management</span></a></li>
<li class="toclevel-2"><a href="#Psychotherapy"><span class="tocnumber">3.3</span> <span class="toctext">Psychotherapy</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Recreational_use"><span class="tocnumber">4</span> <span class="toctext">Recreational use</span></a></li>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">5</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1"><a href="#Formulations"><span class="tocnumber">6</span> <span class="toctext">Formulations</span></a></li>
<li class="toclevel-1"><a href="#Pharmacology"><span class="tocnumber">7</span> <span class="toctext">Pharmacology</span></a>
<ul>
<li class="toclevel-2"><a href="#Pharmacodynamics"><span class="tocnumber">7.1</span> <span class="toctext">Pharmacodynamics</span></a></li>
<li class="toclevel-2"><a href="#Metabolites"><span class="tocnumber">7.2</span> <span class="toctext">Metabolites</span></a></li>
<li class="toclevel-2"><a href="#Analogs"><span class="tocnumber">7.3</span> <span class="toctext">Analogs</span></a></li>
<li class="toclevel-2"><a href="#Isomerism"><span class="tocnumber">7.4</span> <span class="toctext">Isomerism</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Research"><span class="tocnumber">8</span> <span class="toctext">Research</span></a></li>
<li class="toclevel-1"><a href="#Legal_status"><span class="tocnumber">9</span> <span class="toctext">Legal status</span></a></li>
<li class="toclevel-1"><a href="#Canada"><span class="tocnumber">10</span> <span class="toctext">Canada</span></a></li>
<li class="toclevel-1"><a href="#Sweden"><span class="tocnumber">11</span> <span class="toctext">Sweden</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">12</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">13</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">14</span> <span class="toctext">External links</span></a></li>
<li class="toclevel-1"><a href="#Further_reading"><span class="tocnumber">15</span> <span class="toctext">Further reading</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Psychoactive_effects" id="Psychoactive_effects"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=1" title="Edit section: Psychoactive effects">edit</a>]</span> <span class="mw-headline">Psychoactive effects</span></h2>
<p>At doses of around 3–5 mg/kg of body weight, ibogaine has a mild stimulant effect. The high-dose ibogaine experience of 10 mg/kg or greater most commonly occurs as two distinct phases: the visual phase and the introspective phase.</p>
<p>The visual phase is characterized by open-eye visuals, closed-eye visuals, and dreamlike sequences. Objects may be seen as distorted, projecting tracers, or having moving colors or textures. With the eyes closed, extremely detailed and vivid geometric and fractal visions may be seen. Subjective reports often include a movie-like recollection of earlier life experiences as well as dreamlike sequences with symbolism of one's present or anticipated future. Other effects in the visionary phase may include laughing, sensations of euphoria or fear, and temporary short-term memory impairment. The visionary phase usually ends after one to four hours, after which the introspective phase begins.</p>
<p>The introspective phase is typically reported to bring elevated mood, a sense of calm and euphoria, and a distinct intellectual and emotional clarity. Subjects often report being able to accomplish deep emotional and intellectual introspection into psychological and emotional concerns. It is also during this period that opioid addicts first notice the absence of withdrawal cravings. The duration of the introspective phase is highly variable, usually lasting hours but sometimes lasting days.</p>
<p><a name="Side_effects_and_safety" id="Side_effects_and_safety"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=2" title="Edit section: Side effects and safety">edit</a>]</span> <span class="mw-headline">Side effects and safety</span></h2>
<p>One of the first noticeable effects of large-dose ibogaine ingestion is <a href="/wiki/Ataxia" title="Ataxia">ataxia</a>, a difficulty in coordinating muscle motion which makes standing and walking virtually impossible without assistance. <a href="/wiki/Xerostomia" title="Xerostomia">Xerostomia</a> (dry mouth), <a href="/wiki/Nausea" title="Nausea">nausea</a>, and vomiting may follow. These symptoms are long in duration, ranging from 4 to 24 hours in some cases. Ibogaine is sometimes administered by enema to help the subject avoid vomiting up the dose. Psychiatric medications are strongly contraindicated in ibogaine therapy due to adverse interactions. Some studies also suggest the possibility of adverse interaction with heart conditions. In one study of canine subjects, ibogaine was observed to increase <a href="/wiki/Sinus_arrhythmia" title="Sinus arrhythmia">sinus arrhythmia</a> (the normal change in heart rate during respiration).<sup id="cite_ref-1" class="reference"><a href="#cite_note-1" title=""><span>[</span>2<span>]</span></a></sup> Ventricular <a href="/wiki/Ectopy" title="Ectopy" class="mw-redirect">ectopy</a> has been observed in a minority of patients during ibogaine therapy.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2" title=""><span>[</span>3<span>]</span></a></sup> It has been proposed that there is a theoretical risk of QT-interval prolongation following ibogaine administration.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3" title=""><span>[</span>4<span>]</span></a></sup> This risk was further demonstrated by a case reported in the <a href="/wiki/New_England_Journal_of_Medicine" title="New England Journal of Medicine">New England Journal of Medicine</a> documenting <a href="/wiki/Prolonged_QT_interval" title="Prolonged QT interval" class="mw-redirect">prolonged QT interval</a> and <a href="/wiki/Ventricular_tachycardia" title="Ventricular tachycardia">ventricular tachycardia</a> after initial use. <sup id="cite_ref-4" class="reference"><a href="#cite_note-4" title=""><span>[</span>5<span>]</span></a></sup></p>
<p>There are 12 documented fatalities that have been loosely associated with ibogaine ingestion.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5" title=""><span>[</span>6<span>]</span></a></sup> Exact determinations of the cause of death have proven elusive due to the quasi-legal status of ibogaine and the unfamiliarity of medical professionals with this relatively rare substance. No autopsy to date has implicated ibogaine as the sole cause of death. Causes given range from significant pre-existing medical problems to the surreptitious consumption of other drugs in conjunction with ibogaine. Most legal and illegal psychoactive drugs are strongly contraindicated during or immediately after ibogaine treatment, which presents a risk in undersupervised or self-treating subjects.</p>
<p><a name="Therapeutic_uses" id="Therapeutic_uses"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=3" title="Edit section: Therapeutic uses">edit</a>]</span> <span class="mw-headline">Therapeutic uses</span></h2>
<p><a name="Treatment_for_opiate_addiction" id="Treatment_for_opiate_addiction"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=4" title="Edit section: Treatment for opiate addiction">edit</a>]</span> <span class="mw-headline">Treatment for opiate addiction</span></h3>
<p>The most-studied long-term therapeutic effect is that ibogaine seems to catalyze partial or complete interruption of <a href="/wiki/Addiction" title="Addiction">addiction</a> to <a href="/wiki/Opioid" title="Opioid">opioids</a>. An integral effect is the alleviation of symptoms of opioid <a href="/wiki/Withdrawal" title="Withdrawal">withdrawal</a>. Research also suggests that ibogaine may be useful in treating dependence on other substances such as <a href="/wiki/Alcohol" title="Alcohol">alcohol</a>, <a href="/wiki/Methamphetamine" title="Methamphetamine">methamphetamine</a>, and <a href="/wiki/Nicotine" title="Nicotine">nicotine</a> and may affect compulsive behavioral patterns not involving substance abuse or chemical dependence.</p>
<p>Proponents of ibogaine treatment for drug addiction have established formal and informal clinics or self-help groups in <a href="/wiki/Canada" title="Canada">Canada</a>, <a href="/wiki/Mexico" title="Mexico">Mexico</a>, the <a href="/wiki/Caribbean" title="Caribbean">Caribbean</a>, <a href="/wiki/Costa_Rica" title="Costa Rica">Costa Rica</a>, the <a href="/wiki/Czech_Republic" title="Czech Republic">Czech Republic</a>, <a href="/wiki/France" title="France">France</a>, <a href="/wiki/Slovenia" title="Slovenia">Slovenia</a>, the <a href="/wiki/Netherlands" title="Netherlands">Netherlands</a>, <a href="/wiki/Brazil" title="Brazil">Brazil</a>, <a href="/wiki/South_Africa" title="South Africa">South Africa</a>, the <a href="/wiki/United_Kingdom" title="United Kingdom">United Kingdom</a> and <a href="/wiki/New_Zealand" title="New Zealand">New Zealand</a>, where ibogaine is administered as an experimental drug. There also exist <a href="/wiki/Clandestine_chemistry" title="Clandestine chemistry">clandestine</a> drug-treatment facilities in the countries where it is illegal. Although the full nature of ibogaine is still emerging, it appears that the most effective treatment paradigm involves visionary doses of ibogaine of 10–20 mg/kg, producing an interruption of <a href="/wiki/Opiate" title="Opiate">opiate</a> withdrawal and craving. Many users of ibogaine report experiencing visual phenomena during a waking dream state, such as instructive replays of life events that led to their addiction, while others report therapeutic <a href="/wiki/Shaman" title="Shaman" class="mw-redirect">shamanic</a> visions that help them conquer the fears and negative emotions that might drive their addiction. It is proposed that intensive counseling and therapy during the interruption period following treatment is of significant value. Some patients require a second or third treatment session with ibogaine over the course of the next 12 to 18 months, as it will provide a greater efficacy in extinguishing the opiate addiction or other drug dependence syndrome. A minority of patients relapse completely into opiate addiction within days or weeks. A comprehensive article (Lotsof 1995) on the subject of ibogaine therapy detailing the procedure, effects and aftereffects is found in "Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives".<sup id="cite_ref-6" class="reference"><a href="#cite_note-6" title=""><span>[</span>7<span>]</span></a></sup> Ibogaine has also been reported in multiple small-study cohorts to reduce cravings for methamphetamine. <sup id="cite_ref-7" class="reference"><a href="#cite_note-7" title=""><span>[</span>8<span>]</span></a></sup></p>
<p><a name="Chronic_pain_management" id="Chronic_pain_management"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=5" title="Edit section: Chronic pain management">edit</a>]</span> <span class="mw-headline">Chronic pain management</span></h3>
<p>In 1957, Jurg Schneider, a pharmacologist at <a href="/wiki/Ciba" title="Ciba" class="mw-redirect">CIBA</a>, found that ibogaine potentiates <a href="/wiki/Morphine" title="Morphine">morphine</a> <a href="/wiki/Analgesia" title="Analgesia" class="mw-redirect">analgesia</a>.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8" title=""><span>[</span>9<span>]</span></a></sup> Further research was abandoned, and no additional data was ever published by Ciba researchers on ibogaine–opioid interactions. Almost 50 years later, <a href="/wiki/Patrick_Kroupa" title="Patrick Kroupa" class="mw-redirect">Patrick Kroupa</a> and <a href="/w/index.php?title=Hattie_Wells&amp;action=edit&amp;redlink=1" class="new" title="Hattie Wells (page does not exist)">Hattie Wells</a> released the first treatment protocol for concomitant administration of ibogaine with <a href="/wiki/Opioids" title="Opioids" class="mw-redirect">opioids</a> in human subjects, indicating ibogaine reduced tolerance to opioid drugs.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9" title=""><span>[</span>10<span>]</span></a></sup> Kroupa <i>et al.</i> published their research in the <i><a href="/wiki/Multidisciplinary_Association_for_Psychedelic_Studies" title="Multidisciplinary Association for Psychedelic Studies">Multidisciplinary Association for Psychedelic Studies</a> Journal</i> demonstrating that administration of low-"maintenance" doses of ibogaine HCl with <a href="/wiki/Opioids" title="Opioids" class="mw-redirect">opioids</a> decreases <a href="/wiki/Drug_tolerance" title="Drug tolerance">tolerance</a>.</p>
<p><a name="Psychotherapy" id="Psychotherapy"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=6" title="Edit section: Psychotherapy">edit</a>]</span> <span class="mw-headline">Psychotherapy</span></h3>
<p>Ibogaine has been used as an adjunct to <a href="/wiki/Psychotherapy" title="Psychotherapy">psychotherapy</a> by <a href="/wiki/Claudio_Naranjo" title="Claudio Naranjo">Claudio Naranjo</a>, documented in his book <i>The Healing Journey</i>.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10" title=""><span>[</span>11<span>]</span></a></sup></p>
<p><a name="Recreational_use" id="Recreational_use"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=7" title="Edit section: Recreational use">edit</a>]</span> <span class="mw-headline">Recreational use</span></h2>
<p>Casual use of ibogaine in a social or entertainment context is nearly unknown due to its high cost, constrained availability, long duration of effects, and uncomfortable short-term side effects. In the clandestine markets, ibogaine is typically sought as a drug addiction treatment, for ritual spiritual purposes, or psychological introspection.</p>
<p><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=8" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<p>It is uncertain exactly how long iboga has been used in African spiritual practice, but its activity was first observed by French and Belgian explorers in the 19th century. The first botanical description of the <i>Tabernanthe iboga</i> plant was made in 1889. Ibogaine was first isolated from <i>T. <a href="/wiki/Iboga" title="Iboga" class="mw-redirect">iboga</a></i> in 1901 by Dybowski and Landrin<sup id="cite_ref-11" class="reference"><a href="#cite_note-11" title=""><span>[</span>12<span>]</span></a></sup> and independently by Haller and Heckel in the same year using <i>T. iboga</i> samples from <a href="/wiki/Gabon" title="Gabon">Gabon</a>. In the 1930s, ibogaine was sold in France in 8 mg tablets under the name "Lambarene". The total synthesis of ibogaine was accomplished by G. Büchi in 1966.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12" title=""><span>[</span>13<span>]</span></a></sup> Since then, several further totally synthetic routes have been developed.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13" title=""><span>[</span>14<span>]</span></a></sup> The use of ibogaine in treating substance use disorders in human subjects was first observed by <a href="/wiki/Howard_Lotsof" title="Howard Lotsof">Howard Lotsof</a> in 1962, for which he was later awarded <span class="plainlinks"><a href="http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=4499096" class="external text" title="http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=4499096" rel="nofollow">U.S. Patent 4,499,096</a></span><span class="PDFlink noprint"><a href="http://www.pat2pdf.org/pat2pdf/foo.pl?number=4499096" class="external text" title="http://www.pat2pdf.org/pat2pdf/foo.pl?number=4499096" rel="nofollow">&#160;</a></span> in 1985. In 1969, Claudio Naranjo was granted a French patent for the use of ibogaine in psychotherapy.</p>
<p>Ibogaine was placed in US Schedule 1 in 1967 as part of the US government's strong response to the upswing in popularity of psychedelic substances, though iboga itself was scarcely known at the time. Ibogaine's ability to attenuate opioid <a href="/wiki/Withdrawal" title="Withdrawal">withdrawal</a> confirmed in the rat was first published by Dzoljic <i>et al.</i> (1988).<sup id="cite_ref-14" class="reference"><a href="#cite_note-14" title=""><span>[</span>15<span>]</span></a></sup> Ibogaine's use in diminishing <a href="/wiki/Morphine" title="Morphine">morphine</a> self-administration in preclinical studies was shown by Glick <i>et al.</i> (1991)<sup id="cite_ref-15" class="reference"><a href="#cite_note-15" title=""><span>[</span>16<span>]</span></a></sup> and ibogaine's capacity to reduce <a href="/wiki/Cocaine" title="Cocaine">cocaine</a> self-administration in the rat was shown by Cappendijk <i>et al.</i> (1993).<sup id="cite_ref-16" class="reference"><a href="#cite_note-16" title=""><span>[</span>17<span>]</span></a></sup> Animal model support for ibogaine claims to treat <a href="/wiki/Alcohol_dependence" title="Alcohol dependence">alcohol dependence</a> were established by Rezvani (1995).<sup id="cite_ref-17" class="reference"><a href="#cite_note-17" title=""><span>[</span>18<span>]</span></a></sup></p>
<p>The name "Indra extract", in strict terms, refers to 44 kg of an iboga extract manufactured by an unnamed European industrial manufacturer in 1981. This stock was later purchased by Carl Waltenburg, who distributed it under the name "Indra extract". Waltenburg used this extract to treat heroin addicts in <a href="/wiki/Freetown_Christiania" title="Freetown Christiania">Christiania</a>, Denmark, a <a href="/wiki/Squatter" title="Squatter" class="mw-redirect">squatter</a> village where heroin addiction was widespread in 1982.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18" title=""><span>[</span>19<span>]</span></a></sup> Indra extract was offered for sale over the Internet until 2006, when the Indra web presence disappeared. It is unclear whether the extracts currently sold as "Indra extract" are actually from Waltenburg's original stock, or whether any of that stock is even viable or in existence. Ibogaine and related <a href="/wiki/Indole" title="Indole">indole</a> compounds are susceptible to <a href="/wiki/Indole#Oxidation_of_indole" title="Indole">oxidation</a> when exposed to oxygen<sup id="cite_ref-19" class="reference"><a href="#cite_note-19" title=""><span>[</span>20<span>]</span></a></sup>, as opposed to their salt form, which is stable. The exact methods and quality of the original Indra extraction was never documented, so the real composition of the product remains uncertain.</p>
<p>Data demonstrating ibogaine's efficacy in attenuating opioid withdrawal in drug-dependent human subjects was published by Alper <i>et al.</i> (1999)<sup id="cite_ref-20" class="reference"><a href="#cite_note-20" title=""><span>[</span>21<span>]</span></a></sup> and Mash <i>et al.</i> (2000).<sup id="cite_ref-21" class="reference"><a href="#cite_note-21" title=""><span>[</span>22<span>]</span></a></sup></p>
<p>In 1972, journalist <a href="/wiki/Hunter_S._Thompson" title="Hunter S. Thompson">Hunter S. Thompson</a> accused democratic candidate <a href="/wiki/Edmund_Muskie" title="Edmund Muskie">Edmund Muskie</a> of being addicted to ibogaine in a satirical piece. Many readers, and even other journalists, did not realize that Thompson was being facetious. The claim, of course, was completely unfounded, and Thompson himself is documented in the movie <i><a href="/wiki/Gonzo:_The_Life_and_Work_of_Dr._Hunter_S._Thompson" title="Gonzo: The Life and Work of Dr. Hunter S. Thompson">Gonzo: The Life and Work of Dr. Hunter S. Thompson</a></i> discussing the self-fabricated joke of Muskie's alleged ibogaine use and his surprise that anyone actually believed the claim.</p>
<p><a name="Formulations" id="Formulations"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=9" title="Edit section: Formulations">edit</a>]</span> <span class="mw-headline">Formulations</span></h2>
<p>Pure crystalline ibogaine hydrochloride is the most standardized formulation dosing and typically must be produced by the semi-synthesis from <a href="/wiki/Voacangine" title="Voacangine">voacangine</a> in commercial laboratories. In Bwiti religious ceremonies, the rootbark is pulverized and swallowed in large amounts to produce intense psychoactive effects. In Africa, iboga rootbark is sometimes chewed, which releases small amounts of ibogaine to produce a stimulant effect. Ibogaine is also available in a total alkaloid extract of the <i>Tabernanthe iboga</i> plant, which also contains all the other iboga alkaloids and thus has only about one-fifth the potency by weight as standardized ibogaine hydrochloride.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22" title=""><span>[</span>23<span>]</span></a></sup></p>
<p>Total alkaloid extracts of <i>T. iboga</i> are often loosely called "Indra extract". However, that name actually refers to a particular stock of total alkaloid extract produced in Europe in 1981. The fate of that original stock (as well as its original quality) is unknown.</p>
<p><a name="Pharmacology" id="Pharmacology"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=10" title="Edit section: Pharmacology">edit</a>]</span> <span class="mw-headline">Pharmacology</span></h2>
<p>The pharmacology of ibogaine is quite complex, affecting many different <a href="/wiki/Neurotransmitter" title="Neurotransmitter">neurotransmitter</a> systems simultaneously.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23" title=""><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-24" class="reference"><a href="#cite_note-24" title=""><span>[</span>25<span>]</span></a></sup> Because of its fairly low potency at any of its target sites, ibogaine is used in doses anywhere from 5 mg/kg of body weight for a minor effect to 30 mg/kg in the cases of strong polysubstance addiction. It is unknown whether doses greater than 30 mg/kg in humans produce effects that are therapeutically beneficial, medically risky, or simply prolonged in duration. In animal neurotoxicity studies, there was no observable neurotoxicity of ibogaine at 25 mg/kg, but at 50mg/kg, one-third of the rats had developed patches of neurodegeneration, and at doses of 75mg/kg or above, all rats showed a characteristic pattern of degeneration of <a href="/wiki/Purkinje_neurons" title="Purkinje neurons" class="mw-redirect">Purkinje neurons</a>, mainly in the <a href="/wiki/Cerebellum" title="Cerebellum">cerebellum</a>.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25" title=""><span>[</span>26<span>]</span></a></sup> While caution should be exercised when extrapolating animal studies to humans, these results suggest that neurotoxicity of ibogaine is likely to be minimal when ibogaine is used in the 10-20 mg/kg range typical of drug addiction interruption treatment regimes, and indeed death from the other pharmacological actions of the alkaloids is likely to occur by the time the dose is high enough to produce consistent neurotoxic changes.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26" title=""><span>[</span>27<span>]</span></a></sup><sup id="cite_ref-27" class="reference"><a href="#cite_note-27" title=""><span>[</span>28<span>]</span></a></sup></p>
<p><a name="Pharmacodynamics" id="Pharmacodynamics"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=11" title="Edit section: Pharmacodynamics">edit</a>]</span> <span class="mw-headline">Pharmacodynamics</span></h3>
<p>Among recent proposals for ibogaine mechanisms of action is activation of the <a href="/wiki/GDNF" title="GDNF" class="mw-redirect">glial cell line-derived neurotrophic factor</a> (GDNF) pathway in the <a href="/wiki/Ventral_tegmentum" title="Ventral tegmentum">ventral tegmental</a> area (VTA) of the brain. The work has principally been accomplished in preclinical <a href="/wiki/Ethanol" title="Ethanol">ethanol</a> research, where 40 mg/kg of ibogaine caused increases of <a href="/wiki/Ribonucleic_acid" title="Ribonucleic acid" class="mw-redirect">RNA</a> expression of GDNF in keeping with reduction of ethanol intake in the rat, absent neurotoxicity or cell death.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28" title=""><span>[</span>29<span>]</span></a></sup></p>
<p>Ibogaine is a noncompetitive <a href="/wiki/Receptor_antagonist" title="Receptor antagonist">antagonist</a> at α3β4 <a href="/wiki/Nicotinic_receptor" title="Nicotinic receptor" class="mw-redirect">nicotinic receptors</a>, binding with moderate affinity.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29" title=""><span>[</span>30<span>]</span></a></sup> Several other α3β4 antagonists are known, and some of these, such as <a href="/wiki/Bupropion" title="Bupropion">bupropion</a> (Wellbutrin or Zyban), and <a href="/wiki/Mecamylamine" title="Mecamylamine">mecamylamine</a>, have been used for treating <a href="/wiki/Nicotine" title="Nicotine">nicotine</a> addiction. This α3β4 antagonism correlates quite well with the observed effect of interrupting addiction. Co-administration of ibogaine with other α3β4 antagonists such as 18-MC, <a href="/wiki/Dextromethorphan" title="Dextromethorphan">dextromethorphan</a> or mecamylamine had a stronger anti-addictive effect than when it was administered alone.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30" title=""><span>[</span>31<span>]</span></a></sup> Since α3β4 <a href="/wiki/Ion_channel" title="Ion channel">channels</a> and <a href="/wiki/NMDA_channel" title="NMDA channel" class="mw-redirect">NMDA channels</a> are related to each other and their binding sites within the <a href="/wiki/Lumen_(anatomy)" title="Lumen (anatomy)">lumen</a> bind a range of same ligands (e.g. <a href="/wiki/DXM" title="DXM" class="mw-redirect">DXM</a>, <a href="/wiki/Phencyclidine" title="Phencyclidine">PCP</a>),<sup id="cite_ref-31" class="reference"><a href="#cite_note-31" title=""><span>[</span>32<span>]</span></a></sup> some older sources suggested that ibogaine's anti-addictive properties may be (partly) due to it being an <a href="/wiki/NMDA_receptor_antagonist" title="NMDA receptor antagonist">NMDA receptor antagonist</a>.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32" title=""><span>[</span>33<span>]</span></a></sup> However, ligands, like <a href="/wiki/18-methoxycoronaridine" title="18-methoxycoronaridine" class="mw-redirect">18-MC</a>, selective for α3β4- vs. NMDA-channels showed no drop-off in activity.</p>
<p>It is suspected that ibogaine's actions on the <a href="/wiki/Opioid" title="Opioid">opioid</a> and <a href="/wiki/Glutamatergic" title="Glutamatergic" class="mw-redirect">glutamatergic</a> systems are also involved in its anti-addictive effects. Persons treated with ibogaine report a cessation of opioid <a href="/wiki/Withdrawal" title="Withdrawal">withdrawal</a> signs generally within an hour of administration.</p>
<p>Ibogaine is a weak <a href="/wiki/5HT2A_receptor" title="5HT2A receptor" class="mw-redirect">5HT<sub>2A</sub> receptor</a> <a href="/wiki/Agonist" title="Agonist">agonist</a><sup id="cite_ref-33" class="reference"><a href="#cite_note-33" title=""><span>[</span>34<span>]</span></a></sup>, and although it is unclear how significant this action is for the anti-addictive effects of ibogaine, it is likely to be important for the hallucinogenic effects.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34" title=""><span>[</span>35<span>]</span></a></sup> Ibogaine is also a <a href="/wiki/Sigma_receptor" title="Sigma receptor">sigma<sub>2</sub> receptor</a> <a href="/wiki/Agonist" title="Agonist">agonist</a>.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35" title=""><span>[</span>36<span>]</span></a></sup></p>
<p><a name="Metabolites" id="Metabolites"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=12" title="Edit section: Metabolites">edit</a>]</span> <span class="mw-headline">Metabolites</span></h3>
<p>Ibogaine is <a href="/wiki/Metabolite" title="Metabolite">metabolized</a> in the human body by <a href="/wiki/Cytochrome_P450" title="Cytochrome P450">cytochrome P450</a> 2D6, and the major metabolite is <a href="/w/index.php?title=Noribogaine&amp;action=edit&amp;redlink=1" class="new" title="Noribogaine (page does not exist)">noribogaine</a> (12-hydroxyibogamine). Noribogaine is most potent as a <a href="/wiki/Serotonin_reuptake_inhibitor" title="Serotonin reuptake inhibitor" class="mw-redirect">serotonin reuptake inhibitor</a> and acts as a moderate κ- and weak µ-<a href="/wiki/Opioid_receptor" title="Opioid receptor">opioid receptor</a> full agonist and therefore, also has an aspect of an <a href="/wiki/Opiate_replacement_therapy" title="Opiate replacement therapy">opiate replacement</a> similar to compounds like <a href="/wiki/Methadone" title="Methadone">methadone</a>. Both ibogaine and noribogaine have a <a href="/wiki/Elimination_half-life" title="Elimination half-life" class="mw-redirect">plasma half-life</a> of around two hours in the rat<sup id="cite_ref-urlIn_Vivo_Neurobiological_Effects_of_Ibogaine_and_Its_O-Desmethyl_Metabolite.2C_12-Hydroxyibogamine_.28Noribogaine.29.2C_in_Rats_--_Baumann_et_al._297_.282.29:_531_--_Journal_of_Pharmacology_And_Experimental_Therapeutics_36-0" class="reference"><a href="#cite_note-urlIn_Vivo_Neurobiological_Effects_of_Ibogaine_and_Its_O-Desmethyl_Metabolite.2C_12-Hydroxyibogamine_.28Noribogaine.29.2C_in_Rats_--_Baumann_et_al._297_.282.29:_531_--_Journal_of_Pharmacology_And_Experimental_Therapeutics-36" title=""><span>[</span>37<span>]</span></a></sup>, although the half-life of noribogaine is slightly longer than the parent compound. It is proposed that ibogaine is deposited in fat and metabolized into noribogaine as it is released.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37" title=""><span>[</span>38<span>]</span></a></sup> Noribogaine shows higher plasma levels than ibogaine and may therefore be detected for longer periods of time than ibogaine. Noribogaine is also more potent than ibogaine in rat <a href="/w/index.php?title=Drug_discrimination_assay&amp;action=edit&amp;redlink=1" class="new" title="Drug discrimination assay (page does not exist)">drug discrimination assays</a> when tested for the subjective effects of ibogaine.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38" title=""><span>[</span>39<span>]</span></a></sup> Noribogaine differs from ibogaine in that it contains a <a href="/wiki/Hydroxy" title="Hydroxy">hydroxy</a> instead of a <a href="/wiki/Methoxy" title="Methoxy">methoxy</a> <a href="/wiki/Functional_group" title="Functional group">group</a> at the 12 position.</p>
<p><a name="Analogs" id="Analogs"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=13" title="Edit section: Analogs">edit</a>]</span> <span class="mw-headline">Analogs</span></h3>
<p>A synthetic derivative of ibogaine, <a href="/wiki/18-methoxycoronaridine" title="18-methoxycoronaridine" class="mw-redirect">18-methoxycoronaridine</a> (18-MC), is a selective α3β4 antagonist that was developed collaboratively by the neurologist Stanley D. Glick (Albany) and the chemist Martin E. Kuehne (Vermont).<sup id="cite_ref-39" class="reference"><a href="#cite_note-39" title=""><span>[</span>40<span>]</span></a></sup> This discovery was stimulated by earlier studies on other naturally occurring analogues of ibogaine such as <a href="/w/index.php?title=Coronaridine&amp;action=edit&amp;redlink=1" class="new" title="Coronaridine (page does not exist)">coronaridine</a> and <a href="/wiki/Voacangine" title="Voacangine">voacangine</a> that showed these compounds also have anti-addictive properties.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40" title=""><span>[</span>41<span>]</span></a></sup><sup id="cite_ref-41" class="reference"><a href="#cite_note-41" title=""><span>[</span>42<span>]</span></a></sup></p>
<p><a name="Isomerism" id="Isomerism"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=14" title="Edit section: Isomerism">edit</a>]</span> <span class="mw-headline">Isomerism</span></h3>
<p>Ibogaine has two separate chiral centers which means that there a four different stereoisomers of ibogaine. These four isomers are difficult to resolve.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42" title=""><span>[</span>43<span>]</span></a></sup></p>
<p><a name="Research" id="Research"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=15" title="Edit section: Research">edit</a>]</span> <span class="mw-headline">Research</span></h2>
<p>An ibogaine research project was funded by the US <a href="/wiki/National_Institute_on_Drug_Abuse" title="National Institute on Drug Abuse">National Institute on Drug Abuse</a> in the early 1990s. The National Institute on Drug Abuse (NIDA) abandoned efforts to continue this project into clinical studies in 1995, citing other reports that suggested a risk of brain damage with extremely high doses and fatal heart arrhythmia in patients having a history of health problems, as well as inadequate funding for ibogaine development within their budget. However, NIDA funding for ibogaine research continues in indirect grants often cited in peer-reviewed ibogaine publications.</p>
<p>In addition, after years of work and a number of significant changes to the original protocol, on <span class="mw-formatted-date" title="2006-08-17"><span class="mw-formatted-date" title="08-17"><a href="/wiki/August_17" title="August 17">August 17</a></span>, <a href="/wiki/2006" title="2006">2006</a></span>, a <a href="/wiki/Multidisciplinary_Association_for_Psychedelic_Studies" title="Multidisciplinary Association for Psychedelic Studies">MAPS</a>-sponsored research team received "unconditional approval" from a Canadian Institutional Review Board (IRB) to proceed with a long-term observational case study that will examine changes in substance use in 20 consecutive people seeking ibogaine-based addiction treatment for opiate dependence at the Iboga Therapy House in Vancouver.</p>
<p><a name="Legal_status" id="Legal_status"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=16" title="Edit section: Legal status">edit</a>]</span> <span class="mw-headline">Legal status</span></h2>
<p>Ibogaine and its <a href="/wiki/Hydrochloride" title="Hydrochloride">salts</a> were regulated by the U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration" class="mw-redirect">Food and Drug Administration</a> in 1967 pursuant to its enhanced authority to regulate <a href="/wiki/Stimulants" title="Stimulants" class="mw-redirect">stimulants</a>, <a href="/wiki/Depressants" title="Depressants" class="mw-redirect">depressants</a>, and <a href="/wiki/Hallucinogens" title="Hallucinogens" class="mw-redirect">hallucinogens</a> granted by the 1965 Drug Abuse Control Amendments (DACA) to the <a href="/wiki/Federal_Food,_Drug,_and_Cosmetic_Act" title="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</a>. In 1970, with the passage of the <a href="/wiki/Controlled_Substances_Act" title="Controlled Substances Act">Controlled Substances Act</a>, it was classified as a <a href="/wiki/Schedule_I_(US)" title="Schedule I (US)" class="mw-redirect">Schedule I</a>-controlled substance in the United States, along with other psychedelics such as <a href="/wiki/LSD" title="LSD" class="mw-redirect">LSD</a> and <a href="/wiki/Mescaline" title="Mescaline">mescaline</a>. Since that time, several other countries, including Sweden, Denmark, Belgium, and Switzerland, have also banned the sale and possession of ibogaine. Although illegal, ibogaine has been used by hundreds of drug addicts in the United States and abroad. <a href="/wiki/Howard_Lotsof" title="Howard Lotsof">Howard Lotsof</a>, a pioneer in bringing awareness to ibogaine's success in helping hardcore drug dependents to quit their addiction, and others have been offering willing persons the treatment. In the Czech Republic and Slovenia, taking advantage of less prohibitive legal systems, ibogaine has been applied to people coming from the U.S. and other countries seeking a safe haven.</p>
<p><a name="Canada" id="Canada"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=17" title="Edit section: Canada">edit</a>]</span> <span class="mw-headline">Canada</span></h2>
<p>Ibogaine is not scheduled as an illegal drug in Canada. (<a href="http://laws.justice.gc.ca/en/ShowFullDoc/cs/C-38.8///en" class="external free" title="http://laws.justice.gc.ca/en/ShowFullDoc/cs/C-38.8///en" rel="nofollow">http://laws.justice.gc.ca/en/ShowFullDoc/cs/C-38.8///en</a>)</p>
<p><a name="Sweden" id="Sweden"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=18" title="Edit section: Sweden">edit</a>]</span> <span class="mw-headline">Sweden</span></h2>
<p>In early 2006, a non-profit foundation addressing the issue of providing ibogaine for the purpose of addiction interruption within established drug treatment care was formed in Sweden.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43" title=""><span>[</span>44<span>]</span></a></sup></p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=19" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="/wiki/Oneirophrenia" title="Oneirophrenia">Oneirophrenia</a></li>
</ul>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=20" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small">
<ol class="references">
<li id="cite_note-0"><b><a href="#cite_ref-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFK.R._Alper.2C_H.S._Lotsof.2C_C.D._Kaplan2008">K.R. Alper, H.S. Lotsof, C.D. Kaplan (2008). "<a href="http://www.ibogaine.org/subculture.html" class="external text" title="http://www.ibogaine.org/subculture.html" rel="nofollow">The Ibogaine Medical Subculture</a>". <i>J. Ethnopharmacology</i> <b>115</b>: 9–24. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.jep.2007.08.034" class="external text" title="http://dx.doi.org/10.1016%2Fj.jep.2007.08.034" rel="nofollow">10.1016/j.jep.2007.08.034</a></span><span class="printonly">. <a href="http://www.ibogaine.org/subculture.html" class="external free" title="http://www.ibogaine.org/subculture.html" rel="nofollow">http://www.ibogaine.org/subculture.html</a></span><span class="reference-accessdate">. Retrieved on 2008-02-22</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+Ibogaine+Medical+Subculture&amp;rft.jtitle=J.+Ethnopharmacology&amp;rft.aulast=K.R.+Alper%2C+H.S.+Lotsof%2C+C.D.+Kaplan&amp;rft.au=K.R.+Alper%2C+H.S.+Lotsof%2C+C.D.+Kaplan&amp;rft.date=2008&amp;rft.volume=115&amp;rft.pages=9%E2%80%9324&amp;rft_id=info:doi/10.1016%2Fj.jep.2007.08.034&amp;rft_id=http%3A%2F%2Fwww.ibogaine.org%2Fsubculture.html&amp;rfr_id=info:sid/en.wikipedia.org:Ibogaine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-1"><b><a href="#cite_ref-1" title="">^</a></b> <a href="http://www.puzzlepiece.org/ibogaine/literature/gershon1962.pdf" class="external free" title="http://www.puzzlepiece.org/ibogaine/literature/gershon1962.pdf" rel="nofollow">http://www.puzzlepiece.org/ibogaine/literature/gershon1962.pdf</a></li>
<li id="cite_note-2"><b><a href="#cite_ref-2" title="">^</a></b> <a href="http://www.doraweiner.org/aatod_hrc.html" class="external text" title="http://www.doraweiner.org/aatod_hrc.html" rel="nofollow">Dora Weiner Foundation Conferences: 2004, Reports and Exhibits - AATOD and HRC</a></li>
<li id="cite_note-3"><b><a href="#cite_ref-3" title="">^</a></b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16698188&amp;query_hl=2&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16698188&amp;query_hl=2&amp;itool=pubmed_docsum" rel="nofollow">Fatalities after taking ibogaine in addiction trea...[Med Hypotheses. 2006] - PubMed Result</a></li>
<li id="cite_note-4"><b><a href="#cite_ref-4" title="">^</a></b> Hoelen DW, Spiering W, Valk GD <i>Long-QT syndrome induced by the antiaddiction drug ibogaine.</i> N Engl J Med. 2009 Jan 15;360(3):308-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19144953" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/19144953">PMID 19144953</a></li>
<li id="cite_note-5"><b><a href="#cite_ref-5" title="">^</a></b> <a href="http://myeboga.com/fatalities.html" class="external text" title="http://myeboga.com/fatalities.html" rel="nofollow">Ibogaine &amp; Eboga (Related) Recorded Fatalities</a></li>
<li id="cite_note-6"><b><a href="#cite_ref-6" title="">^</a></b> H.S. Lotsof (1995). <a href="http://ibogaine.desk.nl/clin-perspectives.html" class="external text" title="http://ibogaine.desk.nl/clin-perspectives.html" rel="nofollow">Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives</a> (Originally published in MAPS Bulletin (1995) V(3):19-26)</li>
<li id="cite_note-7"><b><a href="#cite_ref-7" title="">^</a></b> AJ Giannini.Drugs of Abuse--Second Edition. Los Angeles, Practice Management Information Corp.,1997.</li>
<li id="cite_note-8"><b><a href="#cite_ref-8" title="">^</a></b> Jurg Schneider (assignee: Ciba Pharmaceuticals), Tabernanthine, Ibogaine Containing Analgesic Compositions. <a href="http://ibogaine.desk.nl/2817623.pdf" class="external text" title="http://ibogaine.desk.nl/2817623.pdf" rel="nofollow">US Patent No. 2,817,623 (1957)</a> (pdf)</li>
<li id="cite_note-9"><b><a href="#cite_ref-9" title="">^</a></b> Patrick K. Kroupa, Hattie Wells (2005): <a href="http://ibogaine.mindvox.com/Articles/MAPS-Ibogaine2.pdf" class="external text" title="http://ibogaine.mindvox.com/Articles/MAPS-Ibogaine2.pdf" rel="nofollow">Ibogaine in the 21st Century. Multidisciplinary Association for Psychedelic Studies. Volume XV, Number 1: 21-25</a> (pdf)</li>
<li id="cite_note-10"><b><a href="#cite_ref-10" title="">^</a></b> C. Naranjo. The Healing Journey. <a href="http://www.ibogaine.desk.nl/naranjo.html" class="external text" title="http://www.ibogaine.desk.nl/naranjo.html" rel="nofollow">Chapter V, Ibogaine: Fantasy and Reality, 197-231, Pantheon Books, Div. Random House,ISBN 0394488261, New York (1973)</a></li>
<li id="cite_note-11"><b><a href="#cite_ref-11" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFJ._Dybowski.2C_E._Landrin1901">J. Dybowski, E. Landrin (1901). "<a href="http://ibogaine.desk.nl/dybowski.html" class="external text" title="http://ibogaine.desk.nl/dybowski.html" rel="nofollow">PLANT CHEMISTRY. Concerning Iboga, its excitement-producing properties, its composition, and the new alkaloid it contains, ibogaine</a>". <i>C. R. Acad. Sci.</i> <b>133</b>: 748<span class="printonly">. <a href="http://ibogaine.desk.nl/dybowski.html" class="external free" title="http://ibogaine.desk.nl/dybowski.html" rel="nofollow">http://ibogaine.desk.nl/dybowski.html</a></span><span class="reference-accessdate">. Retrieved on 2006-06-23</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=PLANT+CHEMISTRY.+Concerning+Iboga%2C+its+excitement-producing+properties%2C+its+composition%2C+and+the+new+alkaloid+it+contains%2C+ibogaine&amp;rft.jtitle=C.+R.+Acad.+Sci.&amp;rft.aulast=J.+Dybowski%2C+E.+Landrin&amp;rft.au=J.+Dybowski%2C+E.+Landrin&amp;rft.date=1901&amp;rft.volume=133&amp;rft.pages=748&amp;rft_id=http%3A%2F%2Fibogaine.desk.nl%2Fdybowski.html&amp;rfr_id=info:sid/en.wikipedia.org:Ibogaine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-12"><b><a href="#cite_ref-12" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFG._B.C3.BCchi.2C_D.L._Coffen.2C_Karoly_Kocsis.2C_P.E._Sonnet.2C_and_Frederick_E._Ziegler1966">G. Büchi, D.L. Coffen, Karoly Kocsis, P.E. Sonnet, and Frederick E. Ziegler (1966). "<a href="http://pubs.acs.org/cgi-bin/abstract.cgi/jacsat/1966/88/i13/f-pdf/f_ja00965a039.pdf" class="external text" title="http://pubs.acs.org/cgi-bin/abstract.cgi/jacsat/1966/88/i13/f-pdf/f_ja00965a039.pdf" rel="nofollow">The Total Synthesis of Iboga Alkaloids</a>" (pdf). <i>J. Am. Chem. Soc.</i> <b>88</b> (13): 3099–3109. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1021%2Fja00965a039" class="external text" title="http://dx.doi.org/10.1021%2Fja00965a039" rel="nofollow">10.1021/ja00965a039</a></span><span class="printonly">. <a href="http://pubs.acs.org/cgi-bin/abstract.cgi/jacsat/1966/88/i13/f-pdf/f_ja00965a039.pdf" class="external free" title="http://pubs.acs.org/cgi-bin/abstract.cgi/jacsat/1966/88/i13/f-pdf/f_ja00965a039.pdf" rel="nofollow">http://pubs.acs.org/cgi-bin/abstract.cgi/jacsat/1966/88/i13/f-pdf/f_ja00965a039.pdf</a></span><span class="reference-accessdate">. Retrieved on 2006-06-23</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+Total+Synthesis+of+Iboga+Alkaloids&amp;rft.jtitle=J.+Am.+Chem.+Soc.&amp;rft.aulast=G.+B%C3%BCchi%2C+D.L.+Coffen%2C+Karoly+Kocsis%2C+P.E.+Sonnet%2C+and+Frederick+E.+Ziegler&amp;rft.au=G.+B%C3%BCchi%2C+D.L.+Coffen%2C+Karoly+Kocsis%2C+P.E.+Sonnet%2C+and+Frederick+E.+Ziegler&amp;rft.date=1966&amp;rft.volume=88&amp;rft.issue=13&amp;rft.pages=3099%E2%80%933109&amp;rft_id=info:doi/10.1021%2Fja00965a039&amp;rft_id=http%3A%2F%2Fpubs.acs.org%2Fcgi-bin%2Fabstract.cgi%2Fjacsat%2F1966%2F88%2Fi13%2Ff-pdf%2Ff_ja00965a039.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Ibogaine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-13"><b><a href="#cite_ref-13" title="">^</a></b> C. Frauenfelder (1999) <a href="http://e-collection.ethbib.ethz.ch/ecol-pool/diss/fulltext/eth13329.pdf" class="external text" title="http://e-collection.ethbib.ethz.ch/ecol-pool/diss/fulltext/eth13329.pdf" rel="nofollow"><i>Doctoral Thesis</i>, page 24</a> (pdf)</li>
<li id="cite_note-14"><b><a href="#cite_ref-14" title="">^</a></b> E.D. Dzoljic <i>et al.</i> (1988): <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3233054&amp;query_hl=9&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3233054&amp;query_hl=9&amp;itool=pubmed_docsum" rel="nofollow">"Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats"</a> Arch. Int. Pharmacodyn. Ther. 294, 64-70</li>
<li id="cite_note-15"><b><a href="#cite_ref-15" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGlick_S.D..2C_Rossman_K..2C_Steindorf_S..2C_Maisonneuve_I.M..2C_and_Carlson_J.N.1991">Glick S.D., Rossman K., Steindorf S., Maisonneuve I.M., and Carlson J.N. (1991). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1868880&amp;dopt=Citation" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1868880&amp;dopt=Citation" rel="nofollow">Effects and aftereffects of ibogaine on morphine self-administration in rats</a>". <i>Eur. J. Pharmacol</i> <b>195</b> (3): 341–345. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2F0014-2999%2891%2990474-5" class="external text" title="http://dx.doi.org/10.1016%2F0014-2999%2891%2990474-5" rel="nofollow">10.1016/0014-2999(91)90474-5</a></span><span class="printonly">. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1868880&amp;dopt=Citation" class="external free" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1868880&amp;dopt=Citation" rel="nofollow">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1868880&amp;dopt=Citation</a></span><span class="reference-accessdate">. Retrieved on 2006-06-24</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Effects+and+aftereffects+of+ibogaine+on+morphine+self-administration+in+rats&amp;rft.jtitle=Eur.+J.+Pharmacol&amp;rft.aulast=Glick+S.D.%2C+Rossman+K.%2C+Steindorf+S.%2C+Maisonneuve+I.M.%2C+and+Carlson+J.N.&amp;rft.au=Glick+S.D.%2C+Rossman+K.%2C+Steindorf+S.%2C+Maisonneuve+I.M.%2C+and+Carlson+J.N.&amp;rft.date=1991&amp;rft.volume=195&amp;rft.issue=3&amp;rft.pages=341%E2%80%93345&amp;rft_id=info:doi/10.1016%2F0014-2999%2891%2990474-5&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fcmd%3DRetrieve%26db%3DPubMed%26list_uids%3D1868880%26dopt%3DCitation&amp;rfr_id=info:sid/en.wikipedia.org:Ibogaine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-16"><b><a href="#cite_ref-16" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFCappendijk_SLT.2C_Dzoljic_MR1993">Cappendijk SLT, Dzoljic MR (1993). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8243561&amp;query_hl=5&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8243561&amp;query_hl=5&amp;itool=pubmed_docsum" rel="nofollow">Inhibitory effects of ibogaine on cocaine self-administration in rats</a>". <i>European Journal of Pharmacology</i> <b>241</b>: 261–265. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2F0014-2999%2893%2990212-Z" class="external text" title="http://dx.doi.org/10.1016%2F0014-2999%2893%2990212-Z" rel="nofollow">10.1016/0014-2999(93)90212-Z</a></span><span class="printonly">. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8243561&amp;query_hl=5&amp;itool=pubmed_docsum" class="external free" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8243561&amp;query_hl=5&amp;itool=pubmed_docsum" rel="nofollow">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8243561&amp;query_hl=5&amp;itool=pubmed_docsum</a></span><span class="reference-accessdate">. Retrieved on 2006-06-25</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Inhibitory+effects+of+ibogaine+on+cocaine+self-administration+in+rats&amp;rft.jtitle=European+Journal+of+Pharmacology&amp;rft.aulast=Cappendijk+SLT%2C+Dzoljic+MR&amp;rft.au=Cappendijk+SLT%2C+Dzoljic+MR&amp;rft.date=1993&amp;rft.volume=241&amp;rft.pages=261%E2%80%93265&amp;rft_id=info:doi/10.1016%2F0014-2999%2893%2990212-Z&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fdb%3Dpubmed%26cmd%3DRetrieve%26dopt%3DAbstract%26list_uids%3D8243561%26query_hl%3D5%26itool%3Dpubmed_docsum&amp;rfr_id=info:sid/en.wikipedia.org:Ibogaine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-17"><b><a href="#cite_ref-17" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFRezvani.2C_A..2C_Overstreet_D..2C_and_Lee.2C_Y.1995">Rezvani, A., Overstreet D., and Lee, Y. (1995). "<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8545483&amp;query_hl=1&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8545483&amp;query_hl=1&amp;itool=pubmed_docsum" rel="nofollow">Attenuation of alcohol intake by ibogaine in three strains of alcohol preferring rats.</a>". <i>Pharmacology, Biochemistry, and Behaviour</i> <b>52</b>: 615–620. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2F0091-3057%2895%2900152-M" class="external text" title="http://dx.doi.org/10.1016%2F0091-3057%2895%2900152-M" rel="nofollow">10.1016/0091-3057(95)00152-M</a></span><span class="printonly">. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8545483&amp;query_hl=1&amp;itool=pubmed_docsum" class="external free" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8545483&amp;query_hl=1&amp;itool=pubmed_docsum" rel="nofollow">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=8545483&amp;query_hl=1&amp;itool=pubmed_docsum</a></span><span class="reference-accessdate">. Retrieved on 2006-06-25</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Attenuation+of+alcohol+intake+by+ibogaine+in+three+strains+of+alcohol+preferring+rats.&amp;rft.jtitle=Pharmacology%2C+Biochemistry%2C+and+Behaviour&amp;rft.aulast=Rezvani%2C+A.%2C+Overstreet+D.%2C+and+Lee%2C+Y.&amp;rft.au=Rezvani%2C+A.%2C+Overstreet+D.%2C+and+Lee%2C+Y.&amp;rft.date=1995&amp;rft.volume=52&amp;rft.pages=615%E2%80%93620&amp;rft_id=info:doi/10.1016%2F0091-3057%2895%2900152-M&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Fdb%3Dpubmed%26cmd%3DRetrieve%26dopt%3DAbstract%26list_uids%3D8545483%26query_hl%3D1%26itool%3Dpubmed_docsum&amp;rfr_id=info:sid/en.wikipedia.org:Ibogaine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-18"><b><a href="#cite_ref-18" title="">^</a></b> <a href="http://www.ibogaine.org/history.html" class="external text" title="http://www.ibogaine.org/history.html" rel="nofollow">A Contemporary History of Ibogaine in the United States and Europe</a></li>
<li id="cite_note-19"><b><a href="#cite_ref-19" title="">^</a></b> a)Taylor WI (1965): "The Iboga and Voacanga Alkaloids" (Journal?), Pages 203, 207 and 208. Oxidation products: <a href="/wiki/Peroxide" title="Peroxide">peroxides</a>; indolenine, iboquine and iboluteine. <a href="http://www.puzzlepiece.org/ibogaine/literature/taylor1965.pdf" class="external text" title="http://www.puzzlepiece.org/ibogaine/literature/taylor1965.pdf" rel="nofollow">pdf</a> b) Also compare <a href="http://www.ncbi.nlm.nih.gov/pubmed/16959135" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16959135">PMID 16959135</a></li>
<li id="cite_note-20"><b><a href="#cite_ref-20" title="">^</a></b> Alper <i>et al.</i> (1999) <a href="http://www.ibogaine.desk.nl/p234_s.pdf" class="external text" title="http://www.ibogaine.desk.nl/p234_s.pdf" rel="nofollow">"Treatment of acute opioid withdrawal with ibogaine."</a> Am J Addict. 1999 Summer;8(3):234-42 (pdf)</li>
<li id="cite_note-21"><b><a href="#cite_ref-21" title="">^</a></b> D.C. Mash, <i>et al.</i> (2000). <a href="http://ibogaine.mindvox.com/Articles/Mash-01.pdf" class="external text" title="http://ibogaine.mindvox.com/Articles/Mash-01.pdf" rel="nofollow">Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures</a> (pdf). Neurobiological Mechanisms of Drugs of Abuse Volume 914 of the Annals of the New York Academy of Sciences, September 2000.</li>
<li id="cite_note-22"><b><a href="#cite_ref-22" title="">^</a></b> <a href="http://www.erowid.org/references/refs_view.php?ID=6466" class="external text" title="http://www.erowid.org/references/refs_view.php?ID=6466" rel="nofollow">Jenks CW (2002)</a></li>
<li id="cite_note-23"><b><a href="#cite_ref-23" title="">^</a></b> P. Popik, P. Skolnick (1998). Pharmacology of Ibogaine and Ibogaine-Related Alkaloids. <a href="http://www.ibogaine.desk.nl/alkaloids.html" class="external text" title="http://www.ibogaine.desk.nl/alkaloids.html" rel="nofollow"><i>The Alkaloids</i> <b>52</b>, Chapter 3, 197-231, Academic Press, Editor: G.A. Cordell</a></li>
<li id="cite_note-24"><b><a href="#cite_ref-24" title="">^</a></b> K.R. Alper (2001). Ibogaine: A Review. <a href="http://ibogaine.org/ch01.pdf" class="external text" title="http://ibogaine.org/ch01.pdf" rel="nofollow"><i>The Alkaloids</i> <b>56</b>, 1-38, Academic Press</a> (pdf)</li>
<li id="cite_note-25"><b><a href="#cite_ref-25" title="">^</a></b> Xu Z, Chang LW, Slikker W Jr, Ali SF, Rountree RL, Scallet AC. A dose-response study of ibogaine-induced neuropathology in the rat cerebellum. <i>Toxicological Sciences</i>. 2000 Sep;57(1):95-101. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10966515" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10966515">PMID 10966515</a></li>
<li id="cite_note-26"><b><a href="#cite_ref-26" title="">^</a></b> Kontrimaviciūte V, Mathieu O, Mathieu-Daudé JC, Vainauskas P, Casper T, Baccino E, Bressolle FM. Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub. <i>Journal of Analytical Toxicology</i>. 2006 Sep;30(7):434-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16959135" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16959135">PMID 16959135</a></li>
<li id="cite_note-27"><b><a href="#cite_ref-27" title="">^</a></b> Maciulaitis R, Kontrimaviciute V, Bressolle F, Briedis V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. <i>Human and Experimental Toxicology</i>. 2008 Mar;27(3):181-94. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18650249" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18650249">PMID 18650249</a></li>
<li id="cite_note-28"><b><a href="#cite_ref-28" title="">^</a></b> He, Dao-Yao <i>et al.</i> (2005): "Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption." Journal of Neuroscience, 25(3), pp. 619–628. <a href="http://www.jneurosci.org/cgi/content/full/25/3/619" class="external text" title="http://www.jneurosci.org/cgi/content/full/25/3/619" rel="nofollow">Fulltext</a></li>
<li id="cite_note-29"><b><a href="#cite_ref-29" title="">^</a></b> Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. European Journal of Pharmacology. 2002 Mar 1;438(1-2):99-105.</li>
<li id="cite_note-30"><b><a href="#cite_ref-30" title="">^</a></b> Glick SD, Maisonneuve IM, Kitchen BA. Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors. European Journal of Pharmacology. 2002 Jul 19;448(2-3):185-91.</li>
<li id="cite_note-31"><b><a href="#cite_ref-31" title="">^</a></b> Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. Journal of Pharmacology and Experimental Therapeutics. 1999 Jan;288(1):88-92.</li>
<li id="cite_note-32"><b><a href="#cite_ref-32" title="">^</a></b> Popik P, Layer RT, Skolnick P (1994): "The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex." Psychopharmacology (Berl), 114(4), 672-4. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=7531855&amp;query_hl=20&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=7531855&amp;query_hl=20&amp;itool=pubmed_docsum" rel="nofollow">Abstract</a></li>
<li id="cite_note-33"><b><a href="#cite_ref-33" title="">^</a></b> Glick SD <i>et al.</i> (1999): "(±)-18-Methoxycoronaridine: A Novel Iboga Alkaloid Congener Having Potential Anti-Addictive Efficacy." CNS Drug Reviews, Vol. 5, No. 1, pp. 27-42, see p. 35. <a href="http://www.nevapress.com/cnsdr/full/5/1/27.pdf" class="external text" title="http://www.nevapress.com/cnsdr/full/5/1/27.pdf" rel="nofollow">Fulltext</a></li>
<li id="cite_note-34"><b><a href="#cite_ref-34" title="">^</a></b> Helsley S, Fiorella D, Rabin RA, Winter JC. Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus. Pharmacology, Biochemistry and Behaviour. 1998 Feb;59(2):419-25.</li>
<li id="cite_note-35"><b><a href="#cite_ref-35" title="">^</a></b> Mach RH, Smith CR, Childers SR (1995): "Ibogaine possesses a selective affinity for sigma 2 receptors." Life Sciences, 57(4), PL57-62. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&amp;DB=pubmed" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&amp;DB=pubmed" rel="nofollow">Abstract</a></li>
<li id="cite_note-urlIn_Vivo_Neurobiological_Effects_of_Ibogaine_and_Its_O-Desmethyl_Metabolite.2C_12-Hydroxyibogamine_.28Noribogaine.29.2C_in_Rats_--_Baumann_et_al._297_.282.29:_531_--_Journal_of_Pharmacology_And_Experimental_Therapeutics-36"><b><a href="#cite_ref-urlIn_Vivo_Neurobiological_Effects_of_Ibogaine_and_Its_O-Desmethyl_Metabolite.2C_12-Hydroxyibogamine_.28Noribogaine.29.2C_in_Rats_--_Baumann_et_al._297_.282.29:_531_--_Journal_of_Pharmacology_And_Experimental_Therapeutics_36-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://jpet.aspetjournals.org/cgi/content/full/297/2/531" class="external text" title="http://jpet.aspetjournals.org/cgi/content/full/297/2/531" rel="nofollow">"In Vivo Neurobiological Effects of Ibogaine and Its O-Desmethyl Metabolite, 12-Hydroxyibogamine (Noribogaine), in Rats -- Baumann et al. 297 (2): 531 -- Journal of Pharmacology And Experimental Therapeutics"</a><span class="printonly">. <a href="http://jpet.aspetjournals.org/cgi/content/full/297/2/531" class="external free" title="http://jpet.aspetjournals.org/cgi/content/full/297/2/531" rel="nofollow">http://jpet.aspetjournals.org/cgi/content/full/297/2/531</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=In+Vivo+Neurobiological+Effects+of+Ibogaine+and+Its+O-Desmethyl+Metabolite%2C+12-Hydroxyibogamine+%28Noribogaine%29%2C+in+Rats+--+Baumann+et+al.+297+%282%29%3A+531+--+Journal+of+Pharmacology+And+Experimental+Therapeutics&amp;rft.atitle=&amp;rft_id=http%3A%2F%2Fjpet.aspetjournals.org%2Fcgi%2Fcontent%2Ffull%2F297%2F2%2F531&amp;rfr_id=info:sid/en.wikipedia.org:Ibogaine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-37"><b><a href="#cite_ref-37" title="">^</a></b> Lindsay B. Hough, Sandra M. Pearl and Stanley D. Glick. Tissue Distribution of Ibogaine After Intraperitoneal and Subscutaneous Administration. Life Sciences 58(7) (1996): 119–122. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=10849889&amp;query_hl=2&amp;itool=pubmed_docsum" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=10849889&amp;query_hl=2&amp;itool=pubmed_docsum" rel="nofollow">Abstract</a></li>
<li id="cite_note-38"><b><a href="#cite_ref-38" title="">^</a></b> C Zubaran MD, M Shoaib Ph.D, IP Stolerman Ph.D, J Pablo MS and DC Mash Ph.D. Noribogaine Generalization to the Ibogaine Stimulus: Correlation with Noribogaine Concentration in Rat Brain. Neuropsychopharmacology (1999) 21 119-126.10.1038/sj.npp.1395327. <a href="http://www.nature.com/npp/journal/v21/n1/abs/1395327a.html;jsessionid=163761FFB11BF6435DAC8B3CAF89A68D" class="external autonumber" title="http://www.nature.com/npp/journal/v21/n1/abs/1395327a.html;jsessionid=163761FFB11BF6435DAC8B3CAF89A68D" rel="nofollow">[1]</a></li>
<li id="cite_note-39"><b><a href="#cite_ref-39" title="">^</a></b> Christopher J. Pace, Stanley D. Glick, Isabelle M. Maisonneuve, Li-Wen Heb, Patrick A. Jokiel, Martin E. Kuehne, Mark W. Fleck. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European Journal of Pharmacology 492 (2004): 159–167.</li>
<li id="cite_note-40"><b><a href="#cite_ref-40" title="">^</a></b> Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW Jr, Carlson JN. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. <i>Brain Research</i>. 1994 Sep 19;657(1-2):14-22. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7820611" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/7820611">PMID 7820611</a></li>
<li id="cite_note-41"><b><a href="#cite_ref-41" title="">^</a></b> <a href="http://www.shvoong.com/medicine-and-health/1611478-antiaddictive-indole-alkaloids-ervatamia-yunnanensis/" class="external text" title="http://www.shvoong.com/medicine-and-health/1611478-antiaddictive-indole-alkaloids-ervatamia-yunnanensis/" rel="nofollow">Tsing Hua. Antiaddictive indole alkaloids in Ervatamia yunnanensis and their bioactivity. <i>Academic Journal of Second Military Medical University</i>. January 28, 2006.</a></li>
<li id="cite_note-42"><b><a href="#cite_ref-42" title="">^</a></b> Shulgin &amp; Shulgin (1997), <a href="/wiki/TiHKAL" title="TiHKAL">TiHKAL</a>, p. 487.</li>
<li id="cite_note-43"><b><a href="#cite_ref-43" title="">^</a></b> <a href="http://www.ibogain.se/" class="external text" title="http://www.ibogain.se/" rel="nofollow">Stiftelsen Iboga´s web site</a></li>
</ol>
</div>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=21" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.erowid.org/chemicals/ibogaine/ibogaine.shtml" class="external text" title="http://www.erowid.org/chemicals/ibogaine/ibogaine.shtml" rel="nofollow">Erowid Ibogaine Vault</a></li>
<li><a href="http://www.ibogaine.desk.nl" class="external text" title="http://www.ibogaine.desk.nl" rel="nofollow">Ibogaine Dossier</a></li>
<li><a href="http://www.ibogaine.co.uk" class="external text" title="http://www.ibogaine.co.uk" rel="nofollow">Ibogaine UK</a></li>
<li><a href="http://ibogaine.mindvox.com" class="external text" title="http://ibogaine.mindvox.com" rel="nofollow">MindVox Ibogaine Site and Forums</a></li>
<li><a href="http://www.ibogaine-research.org" class="external text" title="http://www.ibogaine-research.org" rel="nofollow">The Ibogaine Research Project</a></li>
<li><a href="http://doraweiner.org/bill_of_rights.html" class="external text" title="http://doraweiner.org/bill_of_rights.html" rel="nofollow">Ibogaine Patients' Bill of Rights</a></li>
<li><a href="http://www.kron4.com/Global/story.asp?S=1652207" class="external text" title="http://www.kron4.com/Global/story.asp?S=1652207" rel="nofollow">Ibogaine &amp; Addiction</a></li>
<li><a href="http://cbs5.com/specialreports/local_story_034171611.html" class="external text" title="http://cbs5.com/specialreports/local_story_034171611.html" rel="nofollow">Ibogaine on CBS Channel 5; February, 2005</a></li>
<li><a href="http://books.guardian.co.uk/departments/healthmindandbody/story/0,,1045038,00.html" class="external text" title="http://books.guardian.co.uk/departments/healthmindandbody/story/0,,1045038,00.html" rel="nofollow">Ten years of therapy in one night</a></li>
<li><a href="http://userpages.umbc.edu/~jfreed1/Ibogaine.html" class="external text" title="http://userpages.umbc.edu/~jfreed1/Ibogaine.html" rel="nofollow">Ibogaine: A Novel Anti-Addictive Compound - A Comprehensive Literature Review</a></li>
<li><a href="http://www.utne.com/2008-11-01/Science-Technology/An-Addicts-Last-Refuge.aspx" class="external text" title="http://www.utne.com/2008-11-01/Science-Technology/An-Addicts-Last-Refuge.aspx" rel="nofollow">Ibogaine article from Utne Reader</a></li>
</ul>
<p><a name="Further_reading" id="Further_reading"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Ibogaine&amp;action=edit&amp;section=22" title="Edit section: Further reading">edit</a>]</span> <span class="mw-headline">Further reading</span></h2>
<ul>
<li><a href="/wiki/Daniel_Pinchbeck" title="Daniel Pinchbeck">Daniel Pinchbeck</a> writes of his own experience with ibogaine (among other psychoactives) in <i><a href="/wiki/Breaking_Open_the_Head" title="Breaking Open the Head">Breaking Open the Head</a></i>.</li>
<li><a href="http://www.lunartproductions.com/index.php?id=135" class="external text" title="http://www.lunartproductions.com/index.php?id=135" rel="nofollow"><i>Ibogaine: Rite Of Passage</i></a> is a documentary film about the use of ibogaine in Bwiti tradition and addiction medicine.</li>
</ul>
<table class="navbox" cellspacing="0" style=";">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse" style="width:100%;background:transparent;color:inherit;;">
<tr>
<th style=";" colspan="2" class="navbox-title">
<div style="float:left; width:6em;text-align:left;">
<div class="noprint plainlinksneverexpand navbar" style="background:none; padding:0; font-weight:normal;;;border:none;; font-size:xx-small;"><a href="/wiki/Template:TiHKAL" title="Template:TiHKAL"><span title="View this template" style=";;border:none;">v</span></a>&#160;•&#160;<a href="/wiki/Template_talk:TiHKAL" title="Template talk:TiHKAL"><span title="Discussion about this template" style=";;border:none;">d</span></a>&#160;•&#160;<a href="http://en.wikipedia.org/w/index.php?title=Template:TiHKAL&amp;action=edit" class="external text" title="http://en.wikipedia.org/w/index.php?title=Template:TiHKAL&amp;action=edit" rel="nofollow"><span title="Edit this template" style=";;border:none;;">e</span></a></div>
</div>
<span style="font-size:110%;">Drugs from <a href="/wiki/TiHKAL" title="TiHKAL">TiHKAL</a></span></th>
</tr>
<tr style="height:2px;">
<td></td>
</tr>
<tr>
<td colspan="2" style="width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em">
<div>
<p><a href="/wiki/AL-LAD" title="AL-LAD">AL-LAD</a> • <a href="/wiki/Dibutyltryptamine" title="Dibutyltryptamine">DBT</a> • <b><a href="/wiki/Diethyltryptamine" title="Diethyltryptamine">DET</a></b> • <a href="/wiki/Diisopropyltryptamine" title="Diisopropyltryptamine">DiPT</a> • <a href="/wiki/5-MeO-AMT" title="5-MeO-AMT">5-MeO-α-MT</a> • <b><a href="/wiki/Dimethyltryptamine" title="Dimethyltryptamine">DMT</a></b> • <a href="/wiki/2,Alpha-DMT" title="2,Alpha-DMT">2,α-DMT</a> • <a href="/wiki/Alpha,N-DMT" title="Alpha,N-DMT">α,N-DMT</a> • <b><a href="/wiki/Dipropyltryptamine" title="Dipropyltryptamine">DPT</a></b> • <a href="/wiki/Ethylisopropyltryptamine" title="Ethylisopropyltryptamine">EiPT</a> • <a href="/wiki/Alpha-Ethyltryptamine" title="Alpha-Ethyltryptamine">α-ET</a> • <a href="/wiki/ETH-LAD" title="ETH-LAD">ETH-LAD</a> • <a href="/wiki/Harmaline" title="Harmaline">Harmaline</a> • <a href="/wiki/Harmine" title="Harmine">Harmine</a> • <a href="/wiki/4-HO-DBT" title="4-HO-DBT">4-HO-DBT</a> • <a href="/wiki/4-HO-DET" title="4-HO-DET">4-HO-DET</a> • <a href="/wiki/4-HO-DiPT" title="4-HO-DiPT">4-HO-DiPT</a> • <a href="/wiki/4-HO-DMT" title="4-HO-DMT" class="mw-redirect">4-HO-DMT</a> • <b><a href="/wiki/Bufotenin" title="Bufotenin">5-HO-DMT</a></b> • <a href="/wiki/4-HO-DPT" title="4-HO-DPT">4-HO-DPT</a> • <a href="/wiki/4-HO-MET" title="4-HO-MET">4-HO-MET</a> • <a href="/wiki/4-HO-MiPT" title="4-HO-MiPT">4-HO-MiPT</a> • <a href="/wiki/4-HO-MPT" title="4-HO-MPT">4-HO-MPT</a> • <a href="/wiki/4-HO-pyr-T" title="4-HO-pyr-T">4-HO-pyr-T</a> • <b><strong class="selflink">Ibogaine</strong></b> • <b><a href="/wiki/Lysergic_acid_diethylamide" title="Lysergic acid diethylamide">LSD</a></b> • <a href="/wiki/Methylbutyltryptamine" title="Methylbutyltryptamine">MBT</a> • <a href="/wiki/4,5-MDO-DiPT" title="4,5-MDO-DiPT">4,5-MDO-DiPT</a> • <a href="/wiki/5,6-MDO-DiPT" title="5,6-MDO-DiPT">5,6-MDO-DiPT</a> • <a href="/wiki/4,5-MDO-DMT" title="4,5-MDO-DMT">4,5-MDO-DMT</a> • <a href="/wiki/5,6-MDO-DMT" title="5,6-MDO-DMT">5,6-MDO-DMT</a> • <a href="/wiki/5,6-MDO-MiPT" title="5,6-MDO-MiPT">5,6-MDO-MiPT</a> • <a href="/wiki/2-Me-DET" title="2-Me-DET">2-Me-DET</a> • <a href="/wiki/2,N,N-TMT" title="2,N,N-TMT">2-Me-DMT</a> • <b><a href="/wiki/Melatonin" title="Melatonin">Melatonin</a></b> • <a href="/wiki/5-MeO-DET" title="5-MeO-DET">5-MeO-DET</a> • <b><a href="/wiki/5-Methoxy-diisopropyltryptamine" title="5-Methoxy-diisopropyltryptamine">5-MeO-DiPT</a></b> • <b><a href="/wiki/5-MeO-DMT" title="5-MeO-DMT">5-MeO-DMT</a></b> • <a href="/wiki/4-MeO-MiPT" title="4-MeO-MiPT">4-MeO-MiPT</a> • <a href="/wiki/5-MeO-MIPT" title="5-MeO-MIPT" class="mw-redirect">5-MeO-MiPT</a> • <a href="/wiki/5,6-MeO-MiPT" title="5,6-MeO-MiPT">5,6-MeO-MiPT</a> • <a href="/wiki/5-MeO-NMT" title="5-MeO-NMT">5-MeO-NMT</a> • <a href="/wiki/5-MeO-pyr-T" title="5-MeO-pyr-T">5-MeO-pyr-T</a> • <a href="/wiki/6-MeO-THH" title="6-MeO-THH">6-MeO-THH</a> • <a href="/wiki/5-MeO-2,N,N-TMT" title="5-MeO-2,N,N-TMT">5-MeO-TMT</a> • <a href="/wiki/5-MeS-DMT" title="5-MeS-DMT">5-MeS-DMT</a> • <a href="/wiki/N-Methyl-N-isopropyltryptamine" title="N-Methyl-N-isopropyltryptamine">MiPT</a> • <a href="/wiki/Alpha-Methyltryptamine" title="Alpha-Methyltryptamine">α-MT</a> • <a href="/wiki/N-Ethyltryptamine" title="N-Ethyltryptamine">NET</a> • <a href="/wiki/N-Methyltryptamine" title="N-Methyltryptamine">NMT</a> • <a href="/wiki/PRO-LAD" title="PRO-LAD">PRO-LAD</a> • <a href="/wiki/Pyr-T" title="Pyr-T">pyr-T</a> • <b><a href="/wiki/Tryptamine" title="Tryptamine">Tryptamine</a></b> • <a href="/wiki/Tetrahydroharmine" title="Tetrahydroharmine" class="mw-redirect">Tetrahydroharmine</a> • <a href="/wiki/Alpha,_N,_O-TMS" title="Alpha, N, O-TMS" class="mw-redirect">α,N,O-TMS</a></p>
</div>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Preprocessor node count: 5161/1000000
Post-expand include size: 60199/2048000 bytes
Template argument size: 19522/2048000 bytes
Expensive parser function count: 0/500
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:2104803-0!1!0!default!!en!2 and timestamp 20090401210622 -->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org/wiki/Ibogaine">http://en.wikipedia.org/wiki/Ibogaine</a>"</div>
			<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks"><a href="/wiki/Special:Categories" title="Special:Categories">Categories</a>:&#32;<span dir='ltr'><a href="/wiki/Category:Indole_alkaloids" title="Category:Indole alkaloids">Indole alkaloids</a></span> | <span dir='ltr'><a href="/wiki/Category:Psychedelics,_dissociatives_and_deliriants" title="Category:Psychedelics, dissociatives and deliriants">Psychedelics, dissociatives and deliriants</a></span> | <span dir='ltr'><a href="/wiki/Category:Iboga" title="Category:Iboga">Iboga</a></span> | <span dir='ltr'><a href="/wiki/Category:Drug_rehabilitation" title="Category:Drug rehabilitation">Drug rehabilitation</a></span> | <span dir='ltr'><a href="/wiki/Category:Serotonin_receptor_agonists" title="Category:Serotonin receptor agonists">Serotonin receptor agonists</a></span> | <span dir='ltr'><a href="/wiki/Category:Sigma_agonists" title="Category:Sigma agonists">Sigma agonists</a></span> | <span dir='ltr'><a href="/wiki/Category:NMDA_receptor_antagonists" title="Category:NMDA receptor antagonists">NMDA receptor antagonists</a></span> | <span dir='ltr'><a href="/wiki/Category:Nicotinic_antagonists" title="Category:Nicotinic antagonists">Nicotinic antagonists</a></span> | <span dir='ltr'><a href="/wiki/Category:VMAT_inhibitors" title="Category:VMAT inhibitors">VMAT inhibitors</a></span> | <span dir='ltr'><a href="/wiki/Category:Drug_addiction" title="Category:Drug addiction">Drug addiction</a></span></div></div>			<!-- end content -->
						<div class="visualClear"></div>
		</div>
	</div>
		</div>
		<div id="column-one">
	<div id="p-cactions" class="portlet">
		<h5>Views</h5>
		<div class="pBody">
			<ul>
	
				 <li id="ca-nstab-main" class="selected"><a href="/wiki/Ibogaine" title="View the content page [c]" accesskey="c">Article</a></li>
				 <li id="ca-talk"><a href="/wiki/Talk:Ibogaine" title="Discussion about the content page [t]" accesskey="t">Discussion</a></li>
				 <li id="ca-edit"><a href="/w/index.php?title=Ibogaine&amp;action=edit" title="You can edit this page. &#10;Please use the preview button before saving. [e]" accesskey="e">Edit this page</a></li>
				 <li id="ca-history"><a href="/w/index.php?title=Ibogaine&amp;action=history" title="Past versions of this page [h]" accesskey="h">History</a></li>			</ul>
		</div>
	</div>
	<div class="portlet" id="p-personal">
		<h5>Personal tools</h5>
		<div class="pBody">
			<ul>
				<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Ibogaine" title="You are encouraged to log in; however, it is not mandatory. [o]" accesskey="o">Log in / create account</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-logo">
		<a style="background-image: url(http://upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
	<div class='generated-sidebar portlet' id='p-navigation'>
		<h5>Navigation</h5>
		<div class='pBody'>
			<ul>
				<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
				<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
				<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content — the best of Wikipedia">Featured content</a></li>
				<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
				<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			</ul>
		</div>
	</div>
	<div id="p-search" class="portlet">
		<h5><label for="searchInput">Search</label></h5>
		<div id="searchBody" class="pBody">
			<form action="/w/index.php" id="searchform"><div>
				<input type='hidden' name="title" value="Special:Search"/>
				<input id="searchInput" name="search" type="text" title="Search Wikipedia [f]" accesskey="f" value="" />
				<input type='submit' name="go" class="searchButton" id="searchGoButton"	value="Go" title="Go to a page with this exact name if one exists" />&nbsp;
				<input type='submit' name="fulltext" class="searchButton" id="mw-searchButton" value="Search" title="Search Wikipedia for this text" />
			</div></form>
		</div>
	</div>
	<div class='generated-sidebar portlet' id='p-interaction'>
		<h5>Interaction</h5>
		<div class='pBody'>
			<ul>
				<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
				<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
				<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="The list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
				<li id="n-contact"><a href="/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact Wikipedia</a></li>
				<li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Donate" title="Support us">Donate to Wikipedia</a></li>
				<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-tb">
		<h5>Toolbox</h5>
		<div class="pBody">
			<ul>
				<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Ibogaine" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
				<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Ibogaine" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
<li id="t-upload"><a href="/wiki/Wikipedia:Upload" title="Upload files [u]" accesskey="u">Upload file</a></li>
<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</a></li>
				<li id="t-print"><a href="/w/index.php?title=Ibogaine&amp;printable=yes" rel="alternate" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				<li id="t-permalink"><a href="/w/index.php?title=Ibogaine&amp;oldid=281154218" title="Permanent link to this version of the page">Permanent link</a></li><li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Ibogaine&amp;id=281154218">Cite this page</a></li>			</ul>
		</div>
	</div>
	<div id="p-lang" class="portlet">
		<h5>Languages</h5>
		<div class="pBody">
			<ul>
				<li class="interwiki-de"><a href="http://de.wikipedia.org/wiki/Ibogain">Deutsch</a></li>
				<li class="interwiki-es"><a href="http://es.wikipedia.org/wiki/Iboga%C3%ADna">Español</a></li>
				<li class="interwiki-fr"><a href="http://fr.wikipedia.org/wiki/Iboga%C3%AFne">Français</a></li>
				<li class="interwiki-hr"><a href="http://hr.wikipedia.org/wiki/Ibogain">Hrvatski</a></li>
				<li class="interwiki-it"><a href="http://it.wikipedia.org/wiki/Ibogaina">Italiano</a></li>
				<li class="interwiki-he"><a href="http://he.wikipedia.org/wiki/%D7%90%D7%99%D7%91%D7%95%D7%92%D7%90%D7%99%D7%9F">עברית</a></li>
				<li class="interwiki-hu"><a href="http://hu.wikipedia.org/wiki/Ibogain">Magyar</a></li>
				<li class="interwiki-nl"><a href="http://nl.wikipedia.org/wiki/Iboga%C3%AFne">Nederlands</a></li>
				<li class="interwiki-ja"><a href="http://ja.wikipedia.org/wiki/%E3%82%A4%E3%83%9C%E3%82%AC%E3%82%A4%E3%83%B3">日本語</a></li>
				<li class="interwiki-no"><a href="http://no.wikipedia.org/wiki/Ibogain">‪Norsk (bokmål)‬</a></li>
				<li class="interwiki-pl"><a href="http://pl.wikipedia.org/wiki/Ibogaina">Polski</a></li>
				<li class="interwiki-fi"><a href="http://fi.wikipedia.org/wiki/Ibogaiini">Suomi</a></li>
				<li class="interwiki-sv"><a href="http://sv.wikipedia.org/wiki/Ibogain">Svenska</a></li>
			</ul>
		</div>
	</div>
		</div><!-- end of the left (by default at least) column -->
			<div class="visualClear"></div>
			<div id="footer">
				<div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="/skins-1.5/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>
				<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="/images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>
			<ul id="f-list">
					<li id="lastmod"> This page was last modified on 1 April 2009, at 21:06.</li>
					<li id="copyright">All text is available under the terms of the <a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Copyrights" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc.</a>, a U.S. registered <a class='internal' href="http://en.wikipedia.org/wiki/501%28c%29#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="http://en.wikipedia.org/wiki/Non-profit_organization" title="Non-profit organization">nonprofit</a> <a href="http://en.wikipedia.org/wiki/Charitable_organization" title="Charitable organization">charity</a>.<br /></li>
					<li id="privacy"><a href="http://wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
					<li id="about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
					<li id="disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
			</ul>
		</div>
</div>

		<script type="text/javascript">if (window.runOnloadHook) runOnloadHook();</script>
<!-- Served by srv181 in 0.062 secs. --></body></html>
